Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
Dr. Billy Dunn joins the Prothena Board of Directors (Photo: Business Wire)
“For nearly two decades, Dr. Dunn has dedicated his career as a public servant to bringing new and innovative products to patients suffering from neurodegenerative diseases through his leadership role at the FDA. His wealth of experience in regulatory and clinical development, combined with his passion for helping patients, will greatly benefit the millions that are affected by diseases caused by protein dysregulation as the company continues to advance its robust pipeline,” commented Lars G. Ekman, M.D., Ph.D., Chair of Prothena’s Board of Directors. “We look forward to working closely with Dr. Dunn with a shared vision to make meaningful differences for patients.”
“I am excited to join at this transformational time for Prothena. The company’s expertise in pioneering therapies targeting protein dysregulation is clearly reflected in its diverse and promising pipeline guided by a commitment to patient-focused drug development, a patient-first approach that I strongly support,” said Dr. Dunn. “I look forward to working with my fellow board members and the entire team at Prothena to continue advancing novel and next-generation medicines for neurodegenerative and rare peripheral amyloid diseases that have the potential to positively impact millions of people around the globe. These potential medicines include an Alzheimer’s disease pipeline with next-generation anti-amyloid beta and tau-targeted antibodies, and a vaccine that could be used in prevention paradigms.”
During his tenure at FDA, Dr. Dunn had a significant impact on how drugs are developed for a range of serious neurological diseases, including many that previously had only limited treatment options. His work and leadership contributed to major therapeutic advances in neuro-immunological diseases such as multiple sclerosis and myasthenia gravis, advances in rare neurological disorders, advances in migraine treatment, advances in the range of complex seizure disorders, and advances in therapies for Alzheimer’s disease, among many other neurological disorders.
Dr. Dunn is the founding director of the Office of Neuroscience, CDER, at the FDA, a position he held since the founding of the office in 2019 through February 2023. He was responsible for the regulatory oversight of all research conducted to support neuroscience drug development, including the regulation and review of investigational new drug applications and marketing applications for drug and biologic products. From 2005 to 2019, he held positions of increasing seniority in the Division of Neurology Products, CDER, including his role as director of that division.
Dr. Dunn is a trained neurologist and vascular neurologist with experience in basic research, clinical research, and clinical care. He earned his B.A. from the University of
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005750/en/
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Investors
IR@prothena.com
Source: Prothena Corporation plc
